The Oncologic Drugs Advisory Committee (ODAC) made its opinion clear on Thursday that the data from Oncopeptides’ Pepaxto and Spectrum Pharmaceuticals’ Pozenveo are not convincing enough to gain FDA approval. Pepaxto received accelerated approval last February to treat relapsed or refractory multiple myeloma (RRMM). Oncopeptides completed confirmatory trials for the drug that ODAC deemed did more harm than good. Spectrum sought accelerated approval for its non-small cell lung cancer (NSCLC)-focused drug, Pozenveo, which the committee did not find worthy of approval recommendation based on the presented data.